Angiotech partner to release long-term clinical trial results on market-leading TAXUS(R) Express(2)(TM) coronary stent system at
10 Oktober 2005 - 4:00PM
PR Newswire (US)
VANCOUVER, Oct. 10 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) corporate
partner Boston Scientific Corporation ("BSC") today announced the
schedule of their major events and press announcements at the
Transcatheter Cardiovascular Therapeutics (TCT) conference, which
runs from October 16 to 21 in Washington, D.C. BSC will be
announcing long-term efficacy data on its TAXUS(TM) Express(2)(TM)
paclitaxel-eluting stent system, including results from the TAXUS
I, II, IV and VI clinical trials, as well as data from the ARRIVE,
MILESTONE II and OLYMPIA "real-world" registries. Together, these
studies represent more than 38,000 patients. The TAXUS clinical
trials represent the largest body of randomized drug-eluting stent
data available today. BSC's participation in TCT 2005 will include
16 clinical abstracts, 20 additional scientific presentations and 2
educational symposia. "The data we will present at TCT continues to
reinforce the strengths that make TAXUS the leader in the worldwide
drug-eluting stent market: safety, efficacy and deliverability,"
said Paul LaViolette, Chief Operating Officer of Boston Scientific.
"The long-term data from our TAXUS program shows a sustained
efficacy benefit out to four years and an established "real-world"
safety record. The quality and rigor of our clinical trials has
also raised the bar regarding the use of evidence based medicine in
determining treatment decisions." Schedule of Events Tuesday,
October 18 ------------------- - TAXUS Long-Term Results. BSC will
announce follow-up data on long-term safety and efficacy from four
of its TAXUS paclitaxel-eluting stent clinical trials. Results will
be presented from TAXUS I (up to four years), TAXUS II (up to three
years), TAXUS IV (up to three years), and TAXUS VI (up to two
years). BSC will issue a press release summarizing data from all
four clinical trials. - Symposium on Drug-Eluting Stents. From
8:00-10:00 p.m., BSC will host an evening symposium entitled
"Drug-Eluting Stents 2005: Challenges Overcome, Frontiers Yet to
Conquer" chaired by Gregg W. Stone, M.D. and Sigmund Silber, M.D.,
in the Grand Ballroom of the Renaissance Hotel. Topics will include
durability of DES trial results, "real-world" studies, diabetes as
a risk factor for restenosis, and evidence based medicine. Speakers
will include Gregg Stone, M.D., Sigmund Silber, M.D., Donald Baim,
M.D., Keith Dawkins, M.D., Stephen Ellis, M.D., John Lasala, M.D.,
and Patrick Serruys, M.D. Wednesday, October 19
--------------------- - Evidence Based Medicine. On Wednesday, BSC
will issue a press release highlighting the importance of pursuing
evidence based medicine through the increased use of randomized
controlled clinical trials. The release will feature comments from
a symposium presentation titled "Evidence Based Medicine and Best
Practices with DES", which will highlight the need for large scale,
multi-center, randomized, controlled trials with a primary clinical
endpoint. Thursday, October 20 -------------------- - OLYMPIA
Registry. On Thursday, BSC will issue a press release announcing
30-day safety data from its OLYMPIA registry, which is designed to
collect and analyze "real-world" clinical outcomes data using BSC's
next-generation TAXUS(R) Liberte(TM) paclitaxel-eluting stent
system in the treatment of patients with coronary artery disease. -
DES Outcomes in Diabetic Patients. On Thursday, BSC will issue a
press release announcing nine-month sub-population data from its
TAXUS V clinical trial, detailing outcomes for its TAXUS Express(2)
paclitaxel-eluting stent in the treatment of diabetic patients,
particularly higher-risk insulin-requiring diabetics. BSC acquired
worldwide exclusive rights from Angiotech to use paclitaxel to coat
its coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. Vancouver-based Angiotech
Pharmaceuticals, Inc. is a specialty pharmaceutical company
pioneering the combination of pharmaceutical compounds with medical
devices and biomaterials to both create novel solutions for poorly
addressed disease states and improve surgical outcomes. To find out
more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," "may" and "will" and words of
similar import, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. FOR ADDITIONAL INFORMATION:
--------------------------- Analysts and Investors: Todd Young,
Vice President Investor Relations and Communications, Angiotech
Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Analysts: Rui Avelar,
Senior Vice President Medical Affairs and Communications, Angiotech
Pharmaceuticals, Inc. (604) 221-7676 ext 6996 Media: Wendy Carhart,
Waggener Edstrom Bioscience, (503) 443-7354, Email: DATASOURCE:
Angiotech Pharmaceuticals, Inc. CONTACT: Analysts and Investors:
Todd Young, Vice President Investor Relations and Communications,
Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext 6933; Analysts:
Rui Avelar, Senior Vice President Medical Affairs and
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext
6996; Media: Wendy Carhart, Waggener Edstrom Bioscience, (503)
443-7354, Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024